Español
Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Breast Cancer Trial Results


  • For Some Breast Cancers, New Drug May Be Treatment Option
    (Posted: 06/13/2012, Updated: 11/29/2012) - Results from an international clinical trial suggest that women with metastatic, HER2-positive breast cancer that is no longer responding to the targeted therapy trastuzumab (Herceptin) may soon have a new treatment option. Women who received the investigational drug trastuzumab emtansine (T-DM1) lived more than 3 months longer without their tumors progressing than women who received the chemotherapy drug capecitabine (Xeloda) and the targeted drug lapatinib (Tykerb).
  • Exercise, Behavioral Therapy Reduce Menopausal Symptoms Caused by Breast Cancer Treatment
    (Posted: 10/25/2012) - Women with breast cancer who were suffering from treatment-related menopausal symptoms experienced symptom relief with cognitive behavioral therapy, physical exercise, or both, according to a Dutch study published October 8, 2012, in the Journal of Clinical Oncology.
  • Exemestane Reduces Breast Cancer Risk in High-Risk Postmenopausal Women
    (Posted: 07/19/2011, Updated: 03/07/2012) - Clinical trial results presented at the 2011 ASCO annual meeting showed that the aromatase inhibitor exemestane (Aromasin®)—commonly used to treat early and advanced-stage breast cancer—substantially reduced the risk of invasive breast cancer in postmenopausal women at high risk of developing the disease.
  • Exemestane Following Tamoxifen Reduces Breast Cancer Recurrences and Prolongs Survival
    (Posted: 02/01/2012) - Long-term follow-up data from a large international phase III trial shows that postmenopausal women with early-stage hormone receptor-positive breast cancer who received 2 to 3 years of tamoxifen and then switched to the drug exemestane (Aromasin®) for a total of 5 years of adjuvant hormone therapy experienced a delay in disease recurrence and a survival advantage, compared with women who took tamoxifen for 5 years.
  • Combination Therapy Shows Promise for Treating Advanced Breast Cancer
    (Posted: 12/21/2011) - Adding the drug everolimus (Afinitor®) to exemestane helped postmenopausal women whose advanced breast cancer had stopped responding to hormonal therapy live about 4 months longer without the disease progressing than women who received exemestane alone.
< Previous  1 2 3 4 5 6 7 8  Next >